From somatostatin to octreotide LAR: evolution of a somatostatin analogue

References

• Webb SM Quality of life in acromegaly. Neuroendocrinology 2006;83:224-9
   PubMed Web of Science ®Google Scholar
• Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006;4:526-47
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25:102-52
   PubMed Web of Science ®Google Scholar
• Melmed S. Acromegaly. N Engl J Med 1990;322:966-77
   PubMed Web of Science ®Google Scholar
• Melmed S. Medical progress: Acromegaly. N Engl J Med 2006;355:2558-73
   PubMed Web of Science ®Google Scholar
• Sanno N, Teramoto A, Osamura RY, et al. Pathology of pituitary tumors. Neurosurg Clin N Am 2003;14:25-39, vi
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Romijn JA, Pereira AM, et al. Current pharmacotherapy for acromegaly: a review. Expert Opin Pharmacother 2005;6:2393-405
   PubMed Web of Science ®Google Scholar
• Kleinberg DL Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs. Rev Endocr Metab Disord 2005;6:29-37
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-40
   PubMed Web of Science ®Google Scholar
• Delaunoit T, Rubin J, Neczyporenko F, et al. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 2005;80:502-6
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Besser GM, Grossman AB The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458-511
   PubMed Web of Science ®Google Scholar
• Robertson RG, Geiger WJ, Davis NB Carcinoid tumors. Am Fam Physician 2006;74:429-34
   PubMed Web of Science ®Google Scholar
• Anthony LB, Kang T, Shyr Y. Malignant carcinoid syndrome: survival in the octreotide LAR era. Proc Am Soc Clin Oncol 2005;abst 4084
   Google Scholar
• Hofland LJ, Lamberts SW The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47
   PubMed Web of Science ®Google Scholar
• Cozzi R, Attanasio R. Octreotide for acromegaly. Expert Rev Endocrinol Metab 2007;2:129-45
   PubMedGoogle Scholar
• Reisine T, Bell GI Molecular properties of somatostatin receptors. Neuroscience 1995;67:777-90
   PubMed Web of Science ®Google Scholar
• Bronstein MD Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res 2006;35:129-34
   PubMed Web of Science ®Google Scholar
• Gillis JC, Noble S, Goa KL Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-99
   PubMed Web of Science ®Google Scholar
• Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45:836-44
   PubMed Web of Science ®Google Scholar
• Chen T, Miller TF, Prasad P, et al. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J Clin Pharmacol 2000;40:475-81
   PubMed Web of Science ®Google Scholar
• Melmed S, Vance ML, Barkan AL, et al. Current status and future opportunities for controlling acromegaly. Pituitary 2002;5:185-96
   PubMedGoogle Scholar
• Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-40
   PubMed Web of Science ®Google Scholar
• Vance ML, Harris AG Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151:1573-8
   PubMed Web of Science ®Google Scholar
• Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117:711-18
   PubMed Web of Science ®Google Scholar
• Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients–a clinical research center study. J Clin Endocrinol Metab 1995; 80:2768-75
   PubMed Web of Science ®Google Scholar
• McKeage K, Cheer S, Wagstaff AJ Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003;63:2473-99
   PubMed Web of Science ®Google Scholar
• Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?. J Clin Endocrinol Metab 2003;88:3090-8
   PubMed Web of Science ®Google Scholar
• Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403
   PubMed Web of Science ®Google Scholar
• Lancranjan I, Atkinson AB Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999;1:105-14
   PubMedGoogle Scholar
• Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-73
   PubMed Web of Science ®Google Scholar
• Murray RD, Melmed S. A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly. J Clin Endocrinol Metab 2008;93:2957-68
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;85:3132-40
   PubMed Web of Science ®Google Scholar
• Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001; 86:1551-7
   PubMed Web of Science ®Google Scholar
• Ferone D, Colao A, van der Lely AJ, et al. Pharmacotherapy or surgery as primary treatment for acromegaly?. Drugs Aging 2000;17:81-92
   PubMed Web of Science ®Google Scholar
• Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 2009;70:757-68
   PubMed Web of Science ®Google Scholar
• Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:61-6
   PubMed Web of Science ®Google Scholar
• Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of GH-secreting pituitary tumors enhances the response to somatostatin analogues in acromegaly. J Clin Endocrinol Metab 2006;91:85-92
   PubMed Web of Science ®Google Scholar
• Losa M, Mortini P, Urbaz L, et al. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 2006;104:899-906
   PubMed Web of Science ®Google Scholar
• Abe T, Ludecke DK Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001;145:137-45
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 1999;84:3551-5
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82:3308-14
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008;93:2984-90
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van den Oever NC, Frolich M, et al. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf) 2003;58:288-95
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Akker S, Chew SL, et al. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 2000;53:719-24
   PubMed Web of Science ®Google Scholar
• Turner HE, Thornton-Jones VA, Wass JA Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2004;61:224-31
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Rizzo E, Lania AG, et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 2008; 158:19-25
   PubMed Web of Science ®Google Scholar
• Lal A, Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol 2006;18:9-15
   PubMed Web of Science ®Google Scholar
• Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-6
   PubMed Web of Science ®Google Scholar
• Dueno MI, Bai JC, Santangelo WC, et al. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987;32:1092-6
   PubMed Web of Science ®Google Scholar
• Viola KV, Sosa JA Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr Opin Oncol 2005;17:24-7
   PubMed Web of Science ®Google Scholar
• Butturini G, Bettini R, Missiaglia E, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006;13: 1213-21
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol 2009;27:4656-63
   Google Scholar
• Arnold R, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. ASCO GI Cancers Symposium abst 121, 2009 Abstract
   Google Scholar
• Arnold R, Muller H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol, ASCO Annual Meeting Proceedings 2009;27:Abst 4508
   Google Scholar
• NCCN Practice Guidelines in Oncology, v.1.2009. Neuroendocrine tumors. 2009. Available at: http://www.nccn.org
   Google Scholar
• Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004;80:244-51
   PubMed Web of Science ®Google Scholar
• Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999; 10(Suppl 2):S31-8
   PubMed Web of Science ®Google Scholar
• Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001;47(Suppl 2):40-53
   PubMedGoogle Scholar
• Corleto VD, Angeletti S, Schillaci O, et al. Long-term octreotide treatment of metastatic carcinoid tumor. Ann Oncol 2000;11:491-3
   PubMed Web of Science ®Google Scholar
• Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-9
   PubMed Web of Science ®Google Scholar
• Koelz A, Kraenzlin M, Gyr K, et al. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma. Gastroenterology 1987;92:527-31
   PubMed Web of Science ®Google Scholar
• Lamberts SW, Pieters GF, Metselaar HJ, et al. Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Acta Endocrinol (Copenh) 1988; 119:561-6
   PubMedGoogle Scholar
• Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-83
   PubMed Web of Science ®Google Scholar
• Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000;23:412-5
   PubMed Web of Science ®Google Scholar
• Janmohamed S, Bloom SR Carcinoid tumours. Postgrad Med J 1997; 73:207-14
   PubMed Web of Science ®Google Scholar
• Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003;17:437-44
   PubMed Web of Science ®Google Scholar
• O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-6
   PubMed Web of Science ®Google Scholar
• Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004;151:107-12
   PubMed Web of Science ®Google Scholar
• Redfern JS, Fortuner WJ Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol 1995;90:1042-52
   PubMed Web of Science ®Google Scholar
• Catnach SM, Anderson JV, Fairclough PD, et al. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly. Gut 1993;34:270-3
   PubMed Web of Science ®Google Scholar
• Paisley AN, Roberts ME, Trainer PJ Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol (Oxf) 2007;66:723-6
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Raulf F, Stolz B, et al. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993;60:245-64
   PubMed Web of Science ®Google Scholar
• Froidevaux S, Eberle AN Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002;66:161-83
   PubMed Web of Science ®Google Scholar
• Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733-42
   PubMed Web of Science ®Google Scholar
• Schally AV, Szepeshazi K, Nagy A, et al. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol Life Sci 2004;61:1042-68
   PubMed Web of Science ®Google Scholar
• Slijkhuis WA, Stadheim L, Hassoun ZM, et al. Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol 2005;39:333-8
   PubMed Web of Science ®Google Scholar
• Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002;49:1245-50
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Teunissen JJ, Kam BL, et al. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am 2007; 21:561-73
   PubMed Web of Science ®Google Scholar
• De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-40
   PubMed Web of Science ®Google Scholar
• Rosenoff SH, Gabrail NY, Conklin R, et al. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. J Support Oncol 2006;4:289-94
   PubMedGoogle Scholar
• Zidan J, Haim N, Beny A, et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 2001;12:227-9
   PubMed Web of Science ®Google Scholar
• Baillie-Johnson HR Octreotide in the management of treatment-related diarrhoea. Anticancer Drugs 1996;7(Suppl 1):11-15
   PubMedGoogle Scholar
• Nikou GC, Toumpanakis C, Katsiari C, et al. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol 2007;13:119-23
   PubMed Web of Science ®Google Scholar
• Gambineri A, Patton L, De Iasio R, et al. Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:3854-62
   PubMed Web of Science ®Google Scholar
• Lustig RH, Greenway F, Velasquez-Mieyer P, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond) 2006;30:331-41
   PubMed Web of Science ®Google Scholar
• Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(Suppl 4):iv1-16
   PubMed Web of Science ®Google Scholar